<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353493</url>
  </required_header>
  <id_info>
    <org_study_id>unclear</org_study_id>
    <nct_id>NCT03353493</nct_id>
  </id_info>
  <brief_title>Neural Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder</brief_title>
  <official_title>Neural, Molecular and Psychological Mechanisms and Predictors of Treatment Response to Mindfulness-based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VIA University College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate neural mechanisms and predictors of
      treatment outcome in Mindfulness-Based Cognitive Therapy (MBCT) for recurrent Major
      Depressive Disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">January 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised to Mindfulness-based cognitive therapy plus treatment as usual, or treatment as usual.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Participants are masked at baseline assessment to treatment allocation. Outcome assessors are masked to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neural connectivity</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Neural connectivity will be measured with functional magnetic resonance (fMRI). Selected a priory region for seed-based analyses: Default mode Network.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mindfulness skills</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Five Factor Mindfulness Questionnaire (FFMQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in decentering</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Experiences Questionaire (EQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rumination</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Rumination Response Scale (RRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in emotional processing bias</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Facial Expression Recognition task (FERT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interoceptive awareness</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Multidimensional Assessment of Interoceptive Awareness (MAIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived stress</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse or recurrence of depression</measure>
    <time_frame>12 months follow up</time_frame>
    <description>Structured clinical interview for DSM-IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Quick Inventory for Depressive Symptomology (QIDS-SR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin gene expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>IL-1, IL-2, IL-4,IL-6, IL-8, IL-10, IL-12p70, IL-13,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin protein expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>IL-1, IL-2, IL-4,IL-6, IL-8, IL-10, IL-12p70, IL-13,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression of norepinephrine transporter</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Norepinephrine transporter (NET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression of glutamate receptor</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Glutamate receptor (GRM7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression of TNF</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in gene expression of tumor necrosis factor (previous nomenclature TNF-alfa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in protein expression of tumor necrosis factor</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Tumor necrosis factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cRP expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>c reactive protein expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NF-kB gene expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Nuclear factor kappa-light-chain-enhancer of activated B cells gene expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NF-kB protein expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Nuclear factor kappa-light-chain-enhancer of activated B cells protein expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in INFG gene expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Interferon gamma gene expresison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interferon gamma protein expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Interferon gamma protein expresison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial DNA Copy Number</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Copy number is assessed using quantitative real-time-PCR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>fMRI BOLD secondary and whole brain analyses</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>fMRI BOLD whole brain analyses (data-driven) and secondary seed-based analyses: As seeds we select medial prefrontal cortex, insula, hippocampus, the amygdala and the dorso-lateral prefrontal cortex.</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Gene expression with focus on genes involved in mitochondrial function, the respiratory chain.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>HG-U133 Plus 2.0 GeneChip (Affymetrix)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Major Depressive Disorder, Recurrent</condition>
  <arm_group>
    <arm_group_label>MBCT + TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness-Based Cognitive Therapy</intervention_name>
    <description>Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams &amp; Teasdale (2013).</description>
    <arm_group_label>MBCT + TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as usual</intervention_name>
    <description>Treatment as usual</description>
    <arm_group_label>MBCT + TAU</arm_group_label>
    <arm_group_label>TAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age above 18 years

          2. Meeting DSM-IV criteria for a history of recurrent Major Depressive Disorder (MDD)
             with or without a current episode of depression

          3. Recurrent MDD evaluated a being the primary disorder.

          4. Danish literacy

        Exclusion Criteria:

          1. A history of schizophrenia, schizoaffective disorder, bipolar disorder, current severe
             substance abuse, organic mental disorder, current/past psychosis, pervasive
             developmental delay, persistent antisocial behaviour, persistent self-injury requiring
             clinical management/therapy

          2. Formal concurrent psychotherapy

          3. Previous Mindfulness-Based Cognitive Therapy/Mindfulness-Based Stress Reduction

          4. Anti-psychotic medication and benzodiazepines

          5. Standard exclusion criteria for undergoing magnetic resonance imaging (MRI) procedures
             for research purposes, i.e., claustrophobia, pregnancy, cardiac pacemaker, prosthetic
             heart valve, neurostimulator, implanted pumps, cochlear implants, non-MR-compatible
             implants or devices.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Maj van der Velden, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Medicine, Aarhus University.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Maj van der Velden</last_name>
    <phone>004529375967</phone>
    <email>am.vandervelden@cas.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Anne Maj van der Velden</investigator_full_name>
    <investigator_title>PhD fellow</investigator_title>
  </responsible_party>
  <keyword>Mindfulness-Based Cognitive Therapy</keyword>
  <keyword>Neural, psychological and molecular mechanisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

